Fly News Breaks for November 13, 2019
Nov 13, 2019 | 06:28 EDT
BTIG analyst Sean Levin assumed coverage on Cerus with a Buy rating, upgrading shares from Neutral, with a $7 price target saying there is no better time to own shares on current weakness. Levin believes a recent FDA guidance document will spur a safer blood supply and strong adoption of CERS' INTERCEPT Platelets. He expects US blood centers to adopt FDA testing of blood for HIV before the March 2021 deadline, which will increase growth rates for Cerus US sales in second half 2020 and beyond.
News For CERS From the Last 2 Days
There are no results for your query CERS